These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19888513)

  • 1. Development of idraparinux and idrabiotaparinux for anticoagulant therapy.
    Harenberg J
    Thromb Haemost; 2009 Nov; 102(5):811-5. PubMed ID: 19888513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
    Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
    Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idraparinux and idrabiotaparinux.
    Harenberg J
    Expert Rev Clin Pharmacol; 2010 Jan; 3(1):9-16. PubMed ID: 22111528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New anticoagulants for treatment of venous thromboembolism.
    Weitz JI
    Circulation; 2004 Aug; 110(9 Suppl 1):I19-26. PubMed ID: 15339877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials.
    Song Y; Li X; Pavithra S; Li D
    PLoS One; 2013; 8(11):e78972. PubMed ID: 24278113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials of new anticoagulants.
    Anderson J; O'Donnell M
    Vnitr Lek; 2006 Mar; 52 Suppl 1():123-6. PubMed ID: 16637460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.
    Equinox Investigators
    J Thromb Haemost; 2011 Jan; 9(1):92-9. PubMed ID: 20946157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging anticoagulants for the treatment of venous thromboembolism.
    Weitz JI
    Thromb Haemost; 2006 Sep; 96(3):274-84. PubMed ID: 16953267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications.
    Fonseca RJ; Santos GR; Mourão PA
    Thromb Haemost; 2009 Nov; 102(5):829-36. PubMed ID: 19888516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.
    Prandoni P; Tormene D; Perlati M; Brandolin B; Spiezia L
    Expert Opin Investig Drugs; 2008 May; 17(5):773-7. PubMed ID: 18447601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.
    Trellu M; Fau JB; Cortez P; Cheng S; Paty I; Boëlle E; Donat F; Sanderink GJ
    Br J Clin Pharmacol; 2013 May; 75(5):1255-64. PubMed ID: 23078631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.
    Paty I; Trellu M; Destors JM; Cortez P; Boëlle E; Sanderink G
    J Thromb Haemost; 2010 Apr; 8(4):722-9. PubMed ID: 20088937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.
    Walenga JM; Jeske WP; Bara L; Samama MM; Fareed J
    Thromb Res; 1997 Apr; 86(1):1-36. PubMed ID: 9172284
    [No Abstract]   [Full Text] [Related]  

  • 19. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
    Petitou M; van Boeckel CA
    Angew Chem Int Ed Engl; 2004 Jun; 43(24):3118-33. PubMed ID: 15199558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin: from animal organ extract to designer drug.
    Middeldorp S
    Thromb Res; 2008; 122(6):753-62. PubMed ID: 17996279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.